One of the most interesting aspects of the XI International Conference on AIDS was the resurrection of the non-nucleoside reverse transcriptase inhibitors, which had been written off a couple of years ago because of resistance problems.
Data indicating their value in combination with nucleoside analogs on surrogate markers of HIV disease led to the approval of Boehringer Ingelheim's Viramune (nevirapine) earlier this month (Marketletter July 8). At the AIDS conference, delegates heard new 12-month data from the pivotal INCAS study, six-month data from which supported the FDA approval.
Julio Montaner, co-chairman of the conference, presented the results of the study, which compared three treatment arms; Glaxo Wellcome's zidovudine plus Bristol-Myers Squibb's didanosine, zidovudine plus nevirapine, and all three drugs together. A total of 152 patients were enrolled into the study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze